Fondaparinux in Pregnancy: Could It Be a Safe Option? A Review of the Literature
Overview
Affiliations
During pregnancy thrombo-prophylaxis could be required in high risk women. If a severe allergic reaction to low-molecular-weight-heparin (LMWH) or a heparin-induced-thrombocytopenia (HIT) occurs, it's mandatory to stop the drug. Fondaparinux could be an effective option. In the present review, the maternal and pregnancy outcomes of 65 pregnancies in women using Fondaparinux were reported. It was well-tolerated and rate of pregnancy complications was similar to that observed in general population. Regarding congenital malformations, further studies are necessary to investigate the safety of the drug.
Safety profiles of fondaparinux in pregnant women: a systematic review and meta-analysis.
Shan D, Han J, Ji Y, Wu Y, Yi K Eur J Clin Pharmacol. 2025; .
PMID: 39836237 DOI: 10.1007/s00228-025-03804-y.
Contemporary Management of Cardiomyopathy and Heart Failure in Pregnancy.
Afari H, Sheehan M, Reza N Cardiol Ther. 2024; 13(1):17-37.
PMID: 38340291 PMC: 10899150. DOI: 10.1007/s40119-024-00351-y.
Management of pregnant patients with pulmonary arterial hypertension.
Zhang X, Huangfu Z Front Cardiovasc Med. 2022; 9:1029057.
PMID: 36440029 PMC: 9684470. DOI: 10.3389/fcvm.2022.1029057.
Risk factors, diagnosis and management of venous thromboembolic disease in pregnancy.
Edebiri O, Ainle F Breathe (Sheff). 2022; 18(2):220018.
PMID: 36337136 PMC: 9584596. DOI: 10.1183/20734735.0018-2022.
Hematologic Findings in Pregnancy: A Guide for the Internist.
Patel P, Balanchivadze N Cureus. 2021; 13(5):e15149.
PMID: 34164247 PMC: 8214837. DOI: 10.7759/cureus.15149.